The earnings call was optimistic, with strong preliminary results for BRTX-100 showing promise beyond FDA benchmarks, a solid financial position, and potential for accelerated approval. However, the positive outlook is tempered by the limited data available and uncertainty around the release of unblinded results.

Company Guidance

During the BioRestorative Q3 2024 earnings call, management provided encouraging guidance based on preliminary data from their Phase II study of BRTX-100. At 26 weeks, 70% of the 10 patients showed significant improvement in both pain and function, as measured by the Visual Analog Scale (VAS) and the Oswestry Disability Index (ODI), surpassing the FDA's efficacy benchmark of a 30% improvement. The company also reported strong financial health, ending the quarter with $13.1 million in cash and marketable securities, and no outstanding debt. Looking forward, BioRestorative is contemplating a 26-week interim analysis and exploring the expansion of BRTX-100 into cervical indications. The company remains optimistic about achieving its Phase II efficacy endpoints and anticipates presenting more comprehensive data in early 2025.

BRTX-100 Phase II Study Preliminary Results

70% of the first 10 patients showed over 30% improvement in both pain and function at 26 weeks, exceeding FDA benchmarks. No severe adverse events reported.

Financial Position

Ended Q3 with $13.1 million in cash, cash equivalents, and marketable securities, with no outstanding debt, providing financial flexibility.

Potential for Accelerated Approval

Encouraging data could lead to accelerated approval; considering the study data as pivotal due to positive trends and FDA's supportive stance on cell therapies.

---

BioRestorative Therapies (BRTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BRTX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 20, 2025	2025 (Q1)	- / -	-0.33	―	―	―
Nov 12, 2024	2024 (Q3)	-0.43 / -0.13	-0.64	79.69% (+0.51)	―
Aug 13, 2024	2024 (Q2)	-0.57 / -0.50	-0.77	35.06% (+0.27)	―	―
May 14, 2024	2024 (Q1)	-0.52 / -0.33	-1.53	78.43% (+1.20)	―	―
May 15, 2018	2018 (Q1)	- / -1560.00	-2240	30.36% (+680.00)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

BRTX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 12, 2024	$1.64	$1.54	-6.10%
Aug 13, 2024	$1.41	$1.40	-0.71%
May 14, 2024	$1.36	$1.37	+0.74%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---

FAQ

When does BioRestorative Therapies (BRTX) report earnings?

BioRestorative Therapies (BRTX) is schdueled to report earning on May 20, 2025, TBA Not Confirmed.

What is BioRestorative Therapies (BRTX) earnings time?

BioRestorative Therapies (BRTX) earnings time is at May 20, 2025, TBA Not Confirmed.

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BRTX EPS forecast?

Currently, no data Available

---

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing